New Approaches for Prostate Cancer Combination Therapy

2008 ◽  
Author(s):  
Luiz F. Zerbini
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
New Approaches

scholarly journals Self-assembled albumin nanoparticles for combination therapy in prostate cancer

2017 ◽  
Vol Volume 12 ◽  
pp. 7777-7787 ◽  
Author(s):  
Huibo Lian ◽  
Jinhui Wu ◽  
Yiqiao Hu ◽  
Hongqian Guo
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Albumin Nanoparticles ◽  
Self Assembled

Anticancer Effect of Combination Therapy of VP16 and Fosfesterol in Hormone-Refractory Prostate Cancer

2008 ◽  
Vol 31 (2) ◽  
pp. 188-194 ◽  
Author(s):  
Haruhito Azuma ◽  
Takeshi Sakamoto ◽  
Satoshi Kiyama ◽  
Takanobu Ubai ◽  
Yatsugu Kotake ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Hormone Refractory Prostate Cancer ◽  
Anticancer Effect ◽  
Hormone Refractory

Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy

1993 ◽  
Vol 150 (3) ◽  
pp. 908-913 ◽  
Author(s):  
André Dupont ◽  
José-Luis Gomez ◽  
Leonello Cusan ◽  
Michael Koutsilieris ◽  
Fernand Labrie
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Advanced Prostate Cancer ◽  
Flutamide Withdrawal

Combination Therapy with Flutamide: The Therapy of Choice from Early to Advanced Stages of Prostate Cancer

1996 ◽  
pp. 63-74 ◽  
Author(s):  
Fernand Labrie ◽  
André Dupont ◽  
Leonello Cusan ◽  
José-Luis Gomez ◽  
Raul Suburu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Advanced Stages

scholarly journals An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1648
Author(s):  
Anie P. Masilamani ◽  
Viviane Dettmer-Monaco ◽  
Gianni Monaco ◽  
Toni Cathomen ◽  
Irina Kuckuck ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Tumor Growth ◽  
Cancer Cells ◽  
Xenograft Model ◽  
Target Cells ◽  
Prostate Cancer Cells ◽  
Mouse Xenograft Model ◽  
Synergistic Cytotoxicity ◽  
3D Spheroids

Background: Upregulation of anti-apoptotic Bcl-2 proteins in advanced prostate cancer leads to therapeutic resistance by prevention of cell death. New therapeutic approaches aim to target the Bcl-2 proteins for the restoration of apoptosis. Methods: The immunotoxin hD7-1(VL-VH)-PE40 specifically binds to the prostate specific membrane antigen (PSMA) on prostate cancer cells and inhibits protein biosynthesis. It was tested with respect to its effects on the expression of anti-apoptotic Bcl-2 proteins. Combination with the BAD-like mimetic ABT-737 was examined on prostate cancer cells and 3D spheroids and in view of tumor growth and survival in the prostate cancer SCID mouse xenograft model. Results: The immunotoxin led to a specific inhibition of Mcl-1 and Bcl2A1 expression in PSMA expressing target cells. Its combination with ABT-737, which inhibits Bcl-2, Bcl-xl, and Bcl-w, led to an induction of the intrinsic apoptotic pathway and to a synergistic cytotoxicity in prostate cancer cells and 3D spheroids. Furthermore, combination therapy led to a significantly prolonged survival of mice bearing prostate cancer xenografts based on an inhibition of tumor growth. Conclusion: The combination therapy of anti-PSMA immunotoxin plus ABT-737 represents the first tumor-specific therapeutic approach on the level of Bcl-2 proteins for the induction of apoptosis in prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document